Results from a phase I clinical study of the novel Ii-key/HER-2/neu(776- 790) hybrid peptide vaccine in patients with prostate cancer

Clinical Cancer Research

Volumn 16, Issue 13, 2010, Pages 3495-3506

  Perez, Sonia A ^a   Kallinteris, Nikoletta L ^c   Bisias, Stratos ^a   Tzonis, Panagiotis K ^a   Georgakopoulou, Katerina ^a   Varla Leftherioti, Marighoula ^b   Papamichail, Michael ^a   Thanos, Anastasios ^a   Von Hofe, Eric ^c   Baxevanis, Constantin N ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b HELENA VENIZELOU HOSPITAL   (Greece)

^c Antigen Express Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AE37; BICALUTAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GONADORELIN; PEPTIDE VACCINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLISTER; BLOOD LEVEL; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG HYPERSENSITIVITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNITY; MALE; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; REGULATORY T LYMPHOCYTE; SKIN MANIFESTATION; STAINING; SWELLING;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CANCER VACCINES; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; VACCINES, SUBUNIT;

EID: 77954235468     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0085     Document Type: Article

References (45)

1. Scherr D, Swindle PW, Scardino PT. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 2003;61:14-24.
2. Mancuso A, Oudard S, Sternberg CN. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. Crit Rev Oncol Hematol 2007;61:176-85.
3. Zhang Q, Jang TL, Yang X, et al. Infiltration of tumor-reactive transforming growth factor-â insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells. Prostate 2006;66:235-47.
4. McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 2004;91:541-3.
5. Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002;62:2546-53.
6. Wang Y, Harada M, Yano H, et al. Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J Immunother 2005;28:535-41.
7. Hubert RS, Vivanco I, Chen E, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A 1999;96:14523-8.
8. Gulley J, Chen AP, Dahut W, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002; 53:109-17.
9. Kim S, Lee JB, Lee GK, Chang J. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Prostate 2009;69:938-48.
10. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94.
11. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670-9.
12. Kallinteris NL, Lu X, Blackwell CE, von Hofe E, Humphreys RE, Xu M. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. Expert Opin Biol Ther 2006;6:1311-21.
13. Xu M, Capraro GA, Daibata M, Reyes VE, Humphreys RE. Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern. Mol Immunol 1994;31:723-31. (Pubitemid 24244304)
14. Gillogly ME, Kallinteris NL, Xu M, Gulfo JV, Humphreys RE, Murray JL. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother 2004;53:490-6.
15. Kallinteris NL, Wu S, Lu X, von Hofe E, Humphreys RE, Xu M. Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodies. Vaccine 2005;23:2336-8.
16. Kallinteris NL, Wu S, Lu X, Humphreys RE, von Hofe E, Xu M. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope. J Immunother 2005;28:352-8.
17. Sotiriadou R, Perez SA, Gritzapis AD, et al. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 2001;85:1527-34.
18. Voutsas IF, Gritzapis AD, Mahaira LG, et al. Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int J Cancer 2007;121:2031-41.
19. Sotiriadou NN, Kallinteris NL, Gritzapis AD, et al. Ii-Key/HER-2/neu (776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. Cancer Immunol Immunother 2007;56:601-13.
20. Mittendorf EA, Holmes JP, Murray JL, von Hofe E, Peoples GE. CD4+ T cells in antitumor immunity: utility of an Ii-key HER2/neu hybrid peptide vaccine (AE37). Expert Opin Biol Ther 2009;9:71-8.
21. Holmes JP, Benavides LC, Gates JD, et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008;26:3426-33.
22. Osman I, Scher HI, Drobnjak M, et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 2001;7:2643-7.
23. Calvo BF, Levine AM, Marcos M, et al. Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res 2003;9:1087-97.
24. Montironi R, Mazzucchelli R, Barbisan F, et al. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol 2006;37:1137-44.
25. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004;6:517-27. (Pubitemid 39469987)
26. Shariat SF, Bensalah K, Karam JA, et al. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. Clin Cancer Res 2007;13:5377-84.
27. Ricciardelli C, Jackson MW, Choong CS, et al. Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate 2008;68:830-8.
28. Disis ML, Wallace DR, Gooley TA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009;27:4685-92.
29. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006;203:1701-11.
30. de la Cruz-Merino L, Henao-Carrasco F,Garcia-Manrique T, Fernandez-Salguero PM, Codes-Manuel de Villena M. Role of transforming growth factor β in cancer microenvironment. Clin Transl Oncol 2009;11:715-20.
31. Canto EI, Shariat SF, Slawin KM. Biochemical staging of prostate cancer. Urol Clin North Am 2003;30:263-77.
32. Wolff JM, Fandel TH, Borchers H, Jakse G. Serum concentrations of transforming growth factor-β1 in patients with benign and malignant prostatic diseases. Anticancer Res 1999;19:2657-9. (Pubitemid 29392432)
33. Okegawa T, Kinjo M, Nutahara K, Higashihara E. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol 2006;13:1197-201.
34. Savino M, Parrella P, Copetti M, et al. Comparison between real-time quantitative PCR detection of HER2 mRNA copy number in peripheral blood and ELISA of serum HER2 protein for determining HER2 status in breast cancer patients. Cell Oncol 2009;31:203-11.
35. Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 2008;222:129-44.
36. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-32.
37. Wong R, Lau R, Chang J, et al. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Clin Cancer Res 2004;10:5004-13.
38. Phan GQ, Touloukian CE, Yang JC, et al. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 2003;26:349-56.
39. Salazar LG, Fikes J, Southwood S, et al. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating highaffinity binding to multiple class II alleles. Clin Cancer Res 2003;9:5559-65.
40. Keilholz U, Martus P, Scheibenbogen C. Immune monitoring of T-cell responses in cancer vaccine development. Clin Cancer Res 2006;12:2346s-52s.
41. Gannon PO, Alam Fahmy M, Begin LR, et al. Presence of prostate cancer metastasis correlates with lower lymph node reactivity. Prostate 2006;66:1710-20.
42. Yokokawa J, Cereda V, Remondo C, et al. Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008;14:1032-40.
43. Derhovanessian E, Adams V, Hahnel K, et al. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 2009;125:1372-9.
44. Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev 2008;222:316-27.
45. Benavides LC, Gates JD, Carmichael MG, et al. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2009;15:2895-904.